When coverage is not access: A heart transplant recipient’s perspective on everolimus, U.S. Food and Drug Administration labeling, and the problem of “ghost approval”

Read full text Summarise with VIRAT
Authors: Payton E. Herres
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients, yet insurance coverage does not always translate into meaningful access. This perspective introduces the concept of "ghost approval," in which a medication is technically approved but remains financially or logistically inaccessible to the patient. Drawing on a first-person experience with everolimus, an mechanistic target of rapamycin inhibitor without a U.S. Food and Drug Administration indication for heart transplantation, this article highlights the gap between regulatory labeling, clinical practice, and insurance coverage decisions. Despite documented medical necessity and clinical stability, coverage restrictions-including high specialty-tier placement and pharmacy limitations-created substantial barriers to obtaining therapy. This misalignment places patients at risk of treatment interruption and adverse outcomes. Greater alignment between regulatory frameworks, real-world clinical practice, and insurance policy is needed, along with stronger protections to ensure that coverage results in timely, reliable, and affordable access to life-sustaining medications.

Fields of Study & Subjects

Transplantation: Methods and Outcomes Pharmaceutical Economics and Policy Healthcare Policy and Management

Publication details

Journal / source
The Journal of Heart and Lung Transplantation
Volume
45
Issue
7
Pages
1022–1023
Publication date
25 March 2026
Language
EN